Big Pharma wants to develop treatments for rare diseases, with government support. The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) this week launched a new report describing policy priorities to increase research and development into rare diseases. - From Intellectual Property Watch
01/03/2017 by Intellectual Property Watch 1 Comment Big Pharma wants to develop treatments for rare diseases, with government support.
According to the report, “Traditionally, research and development of treatments for rare diseases has been neglected in favour of more common diseases.
This is due to the small numbers of patients, limited epidemiological data on the natural history of many rare diseases, and all stages of research and development being more challenging and lengthy than for more common diseases, it said.
The pharma industry group also called for sustainable access to diagnosis, treatment and care, improving the workforce and infrastructure to treat rare diseases, and developing and strengthening legislation that enhances access to orphan drugs, which are treatments for rare diseases.
"Rare Diseases: Pharma Industry Calls For Collaboration, Political Commitment For Research" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.